Print PDF

Digital Health and Telehealth: Navigating the Current Legal Framework

ABA Health eSource
09.28.2022

The commercialization of digital health and medtech products has significantly increased over the past several years, in part accelerated by the COVID-19 Public Health Emergency (PHE). However, the regulatory waters for many of medtech companies remain murky and the ways in which companies get reimbursed for these services is uncertain and changing. In many instances, digital products are not squarely regulated by the US Food and Drug Administration (FDA) or by the Department of Health and Human Services (HHS) Office of Civil Rights (OCR), which enforces the Health Insurance Portability and Accountability Act (HIPAA). Instead, a patchwork of various state data privacy and security laws may apply, in addition to consumer protection laws. Should a federal framework exist? Or should digital health technology be permitted to flourish with fewer regulatory hurdles?

In an article for the ABA Health eSource, Julia Kadish, Allison Fulton, Arushi Pandya and Ana Anvari of Sheppard Mullin's Digital Health Industry Team, explored these questions, along with the current regulatory regime, and recent rise of industry and non-profits groups working on frameworks and open-access resources to guide medtech companies to the right regulatory path. 

Practice Areas

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.